Cambridge Heart Announces First Quarter Results.

BEDFORD, Mass.--(BW HealthWire)--April 30, 1998--Cambridge Heart, Inc. (NASDAQ:CAMH) today reported revenues of $407,000 for the quarter ended March 31, compared with revenue of $319,000 a year ago. Net loss for the first quarter of 1998 was $1,687,000 or $0.16 per share, compared to a loss of $1,483,000 or $0.14 per share for the same period last year.

Revenue growth continues to be modest, consistent with management's and analysts' expectations, pending the expansion of the Company's labeling claim from the FDA, and the publication of additional studies to confirm the clinical efficacy of its proprietary T-wave alternans technology in identifying patients at risk for ventricular arrhythmias. Expenses and the net loss were also in line with expectations. The increase in expenses reflects planned expansions in clinical trials and marketing programs.

The Company's clinical study for expanding its labeling claim continues to be on track and has over 240 patients enrolled as of this date; enrollment is expected to be completed by the end of May and submission to FDA approximately one month later. Results for the first 148 patients will be presented at the upcoming North American Society for Pacing and Electrophysiology (NASPE) meeting in San Diego by Dr. Michael R. Gold of the University of Maryland School of Medicine -- first on the evening of May 6 in a featured poster presentation and then again on the morning of May 8 at a Company supported symposium on T-wave alternans.

"We are pleased with the progress of our clinical research programs on a broad front, which is resulting in growing awareness of the clinical potential of our T-wave alternans technology," said Jeffrey M. Arnold, Cambridge Heart Chairman, President, and Chief Executive Officer. "This is evidenced by a significant number of both company supported and independent presentations on T-wave alternans at the upcoming NASPE meeting."

In addition, during the first quarter, the Company was granted three new patents providing further protection for the Company's proprietary technologies. One covers the Company's High-Resolution electrode; one the Company's noise reduction methods used for the measurement of T-wave alternans; and one provides further protection for the measurement of T-wave alternans using exercise and other noninvasive means to stress the heart.

Cambridge Heart is engaged in the research, development, and commercialization of products for the noninvasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac death, the early detection of coronary artery disease, and the prompt and accurate diagnosis of heart attack.

Statements made in this news release that are not historical facts include forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are included in Cambridge Heart's Annual Report on Form 10-K for the year ending December 31, 1997. -0-

                         Cambridge Heart, Inc.
                         Financial Highlights

Statement of Operations                   Three months ended March 31,
                                              1998            1997
                                          (Unaudited)     (Unaudited)

Revenues                                 $    406,848    $    319,028

Cost of goods sold                            355,978         305,358
                                            ---------       ---------
                                               50,870          13,670
Costs and expenses
     Research and development               1,006,863         953,713
     Selling, general and administrative      906,747         799,183

           Loss from operations            (1,862,740)     (1,739,226)

Interest income                               175,896         255,784

Net Loss                                 $ (1,686,844)   $ (1,483,442)

Net loss per share basic and diluted     $      (0.16)   $      (0.14)

Weighted average shares outstanding
  basic and diluted                        10,624,486      10,323,606

-0-

Balance Sheet                              March 31,      December 31,
                                             1998             1997
                                          (Unaudited)
Assets
     Cash & Marketable Securities        $ 11,068,240    $ 12,756,341
     Accounts receivable, net                 501,368         509,918
     Inventory                                397,685         416,224
     Other prepaid assets                     292,459         301,127
           Total current assets            12,259,752      13,983,610

     Fixed assets, net                        644,137         574,660
     Other assets                             209,509         190,167
                                           ----------      ----------
                                         $ 13,113,398    $ 14,748,437

Liabilities and stockholders' equity
     Accounts payable and accrued
      expenses                           $    533,870    $    527,137

Stockholders' equity
     Common stock                              10,626          10,606
     Additional paid-in-capital            29,448,300      29,405,685
     Accumulated deficit                  (16,850,148)    (15,163,304)
     Deferred compensation                    (29,250)        (31,687)
           Total stockholders' equity      12,579,528      14,221,300
                                           ----------      ----------
                                         $ 13,113,398    $ 14,748,437

The Company intends to file its quarterly report on Form 10-Q with the
Securities and Exchange Commission shortly. Interested parties are
encouraged to review this report.

-0-

CONTACT: Cambridge Heart, Inc.

Robert Palardy

Evanthia K. Malliris

781/271-1200